# Sensorium Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sensorium-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.sensorium.bio
- Total disclosed funding: $41M
- Latest round: Series A (Aug 19, 2025)
- Investors on record: 13

## About

Based in Massachusetts, US, and founded in 2021 by its CEO Dick Simon, and co-founders Jacob Hooker, Jerry Rosenbaum, and Steve Haggarty, Sensorium Therapeutics, Inc. operates as a biotechnology company that focuses on the research and development of medical drugs for treating mental health illnesses. In August 2025, Sensorium Therapeutics, Inc. raised USD 25 million in Series A funding from investors Dolby Family Ventures, Hatteras Venture Partners, Mission Biocapital, and Mockingbird Credit Partners, with participation from investors CU Healthcare Innovation Fund, Harris Barton Asset Management, Route 66 Ventures, Iter Investments, Ocama Partners, Palo Santo Venture Fund, re.Mind Capital, WPSS.bio, and Sante Ventures. Sensorium Therapeutics, Inc. offers a biodynamic discovery platform that leverages cutting-edge chemistry, neuroscience, and machine learning to identify, reproduce, adapt, and enhance targeted molecules and elevates their utility as modern medicines that can deliver transformational benefits to patients. In addition, the company is also developing SENS-01 as a rapid-acting and well-tolerated therapeutic for patients with anxiety and depression. The company plans to use the series A funding to increase its workforce and to further develop its business. The company will use the August 2025 funding to test a new medicine made from a succulent plant to see if it helps people feel less anxious.

## Funding rounds

- Series A, Aug 19, 2025, $25M — Hatteras Venture Partners, Sante Ventures, Harris Barton Asset Management, Dolby Family Ventures, Route 66 Ventures, Mission Biocapital, Mockingbird Credit Partners, CU Healthcare Innovation Fund, re.Mind Capital, Palo Santo Venture Fund, Iter Investments, Ocama Partners, WPSS.bio
- Series A, Sep 19, 2022, $16M — Sante Ventures, Route 66 Ventures, CU Healthcare Innovation Fund, re.Mind Capital, Palo Santo Venture Fund, Iter Investments, Ocama Partners, WPSS.bio

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A
- Route 66 Ventures (https://capitalatlas.ai/funds/route-66-ventures) — Series A
- CU Healthcare Innovation Fund (https://capitalatlas.ai/funds/cu-healthcare-innovation-fund) — Series A
- re.Mind Capital (https://capitalatlas.ai/funds/re-mind-capital) — Series A
- Palo Santo Venture Fund (https://capitalatlas.ai/funds/palo-santo-venture-fund) — Series A
- Iter Investments (https://capitalatlas.ai/funds/iter-investments) — Series A
- Ocama Partners — Series A
- WPSS.bio — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- Harris Barton Asset Management (https://capitalatlas.ai/funds/harris-barton-asset-management) — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A
- Mockingbird Credit Partners — Series A